DiaMedica (DMAC) Q4 2025 earnings review
FDA Pivot Clouds the Preeclampsia Story, But Cash Runway Remains a Fortress
DiaMedica concluded FY25 with a rock-solid balance sheet ($59.9M in cash), funding operations deep into 2027. However, the operational narrative has materially shifted. In Q3, management described FDA discussions for their U.S. Preeclampsia (PE) trial as 'productive.' This quarter, the company subtly disclosed the FDA is pushing back on animal models, forcing DiaMedica to 'discuss alternate species.' To prevent timelines from stalling, management is pivoting the Phase 2 PE trial to Canada and the UK. Meanwhile, the Phase 2/3 ReMEDy2 stroke trial is Stable and approaching 70% of its interim enrollment target, though R&D expenses are Accelerating as a result.
🐂 Bull Case
By securing a 'No Objection Letter' from Health Canada, DiaMedica bypasses the FDA's preclinical delays, ensuring the Phase 2 early-onset preeclampsia study still kicks off this year.
The massive July 2025 capital raise guarantees a cash runway into 2H 2027. DiaMedica can fund both the ReMEDy2 interim analysis and the PE trials without returning to equity markets.
🐻 Bear Case
The FDA's request for 'alternate species' data implies significant preclinical toxicity re-work for the U.S. Preeclampsia IND. This costs time and money, and delays entry into the world's most lucrative healthcare market.
ReMEDy2 enrollment moved from ~50% in Q3 to 'approaching 70%' in Q4. This implies only ~40 patients were added to the interim cohort over 3 months across roughly 40 global sites—an anemic ~0.3 patients per site per month.
⚖️ Verdict: ⚪
Neutral. The FDA roadblock for the U.S. Preeclampsia trial is a material downgrade from Q3's optimistic narrative. However, the company's strategic pivot to Canada and the sheer size of its cash buffer prevent this from being a thesis-breaker.
Key Themes
FDA Roadblock: The 'Alternate Species' Disclosure
A critical red flag emerged regarding the U.S. Phase 2 Preeclampsia trial. Management noted they must 'discuss alternate species with the FDA' and hope for an update next quarter. In previous calls, management touted their 'productive' FDA pre-IND meetings. This reversal indicates the FDA is not satisfied with the animal models used to prove DM199's safety in pregnancy, effectively stalling the U.S. IND until new toxicology studies are completed.
Geographic Pivot: The Canada/UK Workaround
To counter the U.S. FDA delays, DiaMedica successfully secured a 'No Objection Letter' (NOL) from Health Canada to initiate the Phase 2 early-onset preeclampsia trial there. They also plan to file a clinical trial application in the U.K. in Q2 2026. This is a smart, agile move that keeps the clinical data pipeline flowing while the U.S. regulatory path is negotiated.
Data Contradiction: Stroke Trial 'Momentum' vs The Math
Management continues to express encouragement over the ReMEDy2 stroke trial enrollment. However, the numbers suggest Decelerating or stubbornly slow progress. In Q3 (Sept 2025), enrollment was 'nearing 50%' of the 200-patient target (~100 patients). At Q4 end, it is 'approaching 70%' (~140 patients). Adding roughly 40 patients in a quarter across 35-40 active global sites equates to an enrollment rate of ~0.3 patients per site/month—far below the 1-2 patients/month target management previously cited as optimal.
DM199 Mechanism of Action: The Placental Barrier Advantage
The core technological driver for DiaMedica's pivot into Preeclampsia remains DM199's molecular profile. As a synthetic form of the KLK1 protein, it successfully lowers maternal blood pressure without crossing the placental barrier. This unique safety profile was validated in earlier 2025 IST readouts and remains the primary differentiator against legacy off-label symptom management therapies.
Macro Headwinds: Structural Shifts in Stroke Care
The chronic slowness in ReMEDy2 enrollment is tied to a broader macroeconomic and technological shift in healthcare. As management noted in prior quarters, the rise of AI imaging and teleneurology has altered stroke referral patterns. Smaller community hospitals are treating patients on-site rather than transferring them to the larger research hospitals where DiaMedica's trial sites are located, permanently shrinking the addressable funnel.
Expanding the Preeclampsia IST
While the company-sponsored trials navigate regulatory waters, the Investigator-Sponsored Trial (IST) in South Africa continues to deliver. The expansion cohort for Part 1a will finish in 1H 2026, and the trial is officially expanding into Fetal Growth Restriction (FGR) with the first patient dosing expected in Q2 2026. This allows DiaMedica to capture efficacy signals in adjacent high-need indications at a fraction of the cost.
Other KPIs
Accelerating. Up from $6.4M in Q3 and $5.8M in Q2. Full year R&D came in at $24.6M (vs $19.1M in FY24). This reflects the sheer cost of expanding the ReMEDy2 trial globally to compensate for slow individual site enrollment, as well as preparation costs for the upcoming Phase 2 PE trials.
Accelerating from $7.6M in FY24. The 29% YoY increase was driven heavily by non-cash share-based compensation, team expansion, and heightened patent prosecution and investor relations costs.
Stable compared to the $55.3M reported at the end of Q3 2025, and massively up from the $3.0M entering the year. The July 2025 private placement and recent At-The-Market (ATM) usage have successfully bulletproofed the balance sheet against the rising burn rate.
Guidance
Stable. The company maintains that its $59.9M war chest will easily clear the 2H 2026 interim readout for the stroke trial and fund the initial phases of the Canadian/UK preeclampsia studies without triggering going-concern anxieties.
Stable. The company reaffirmed this timeline, which was pushed back during the Q3 2025 update. Hitting this requires enrolling the remaining ~30% (approx. 60 patients) over the next few quarters, which aligns tightly with their current ~40 patient/quarter trajectory.
Accelerating. Management explicitly guides that R&D will climb as PE clinical development matures and the ReMEDy2 global site footprint continues to expand to meet enrollment requirements.
Key Questions
FDA 'Alternate Species' Details
Can you provide specifics on what the FDA found lacking in the current animal toxicology models for the U.S. Preeclampsia IND, and what is the estimated cost and timeline to complete these new alternate species studies?
Pivotal Trial Implications of Canada/UK Pivot
If the U.S. IND is delayed significantly, will the FDA accept Phase 2 data generated entirely outside the U.S. (Canada/UK/South Africa) for the design and powering of a future U.S. pivotal Phase 3 trial in early-onset preeclampsia?
ReMEDy2 Enrollment Run-Rate Reality
The jump from ~50% to ~70% enrollment over the last quarter implies an addition of roughly 40 patients. Across 35-40 active sites, this is still under 0.5 patients per site per month. What specific operational levers are left to pull if you want to reach the 1-2 patients per month target you previously outlined?